UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Direct Lytic Agents: Novel, Rapidly Acting Potential Antimicrobial Treatment Modalities for Systemic Use in the Era of Rising Antibiotic Resistance

Frontiers in microbiology, 2022-03, Vol.13, p.841905-841905

2022

Volltextzugriff (PDF)

In vitro activity of exebacase against methicillin-resistant Staphylococcus aureus biofilms on orthopedic Kirschner wires

BMC research notes, 2023-09, Vol.16 (1), p.1-5, Article 209

2023

Volltextzugriff (PDF)

Postantibiotic and Sub-MIC Effects of Exebacase (Lysin CF-301) Enhance Antimicrobial Activity against Staphylococcus aureus

Antimicrobial agents and chemotherapy, 2019-06, Vol.63 (6)

2019

Volltextzugriff (PDF)

Arthroscopic “Debridement and Implant Retention” With Local Administration of Exebacase (Lysin CF-301) Followed by Suppressive Tedizolid as Salvage Therapy in Elderly Patients for Relapsing Multidrug-Resistant S. epidermidis Prosthetic Knee Infection

Frontiers in medicine, 2021-05, Vol.8, p.550853-550853

2021

Volltextzugriff (PDF)

Exebacase Demonstrates In Vitro Synergy with a Broad Range of Antibiotics against both Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureus

Antimicrobial agents and chemotherapy, 2020-01, Vol.64 (2)

2020

Volltextzugriff (PDF)

Clinical Trial Design Considerations in Assessing Long-Term Functional Impacts of Tiotropium in COPD: The Uplift Trial

Chronic obstructive pulmonary disease, 2004, Vol.1 (2), p.303-312

2004

Volltextzugriff (PDF)

The Antistaphylococcal Lysin, CF-301, Activates Key Host Factors in Human Blood To Potentiate Methicillin-Resistant Staphylococcus aureus Bacteriolysis

Antimicrobial agents and chemotherapy, 2019-04, Vol.63 (4)

2019

Volltextzugriff (PDF)

Exebacase Is Active In Vitro in Pulmonary Surfactant and Is Efficacious Alone and Synergistic with Daptomycin in a Mouse Model of Lethal Staphylococcus aureus Lung Infection

Antimicrobial agents and chemotherapy, 2021-08, Vol.65 (9), p.e0272320-e0272320

2021

Volltextzugriff (PDF)

In vitro activity of Exebacase (CF-301) against clinical Staphylococcus aureus surveillance isolates from the United States, Europe, and Latin America, 2015–2017

Diagnostic microbiology and infectious disease, 2019-12, Vol.95 (4), p.114879-114879, Article 114879

2019

Volltextzugriff (PDF)

Development of a Broth Microdilution Method for Exebacase Susceptibility Testing

Antimicrobial agents and chemotherapy, 2021-06, Vol.65 (7), p.e0258720-e0258720

2021

Volltextzugriff (PDF)

Antimicrobial Activity of Exebacase (Lysin CF-301) against the Most Common Causes of Infective Endocarditis

Antimicrobial agents and chemotherapy, 2019-10, Vol.63 (10)

2019

Volltextzugriff (PDF)

Correction for Oh et al., “Development of a Broth Microdilution Method for Exebacase Susceptibility Testing”

Antimicrobial agents and chemotherapy, 2021-09, Vol.65 (10), p.e0165821-e0165821

2021

Volltextzugriff (PDF)

Exebacase for patients with Staphylococcus aureus bloodstream infection and endocarditis

The Journal of clinical investigation, 2020-07, Vol.130 (7), p.3750-3760

2020

Volltextzugriff (PDF)

LB12. Exebacase Shows Rapid Symptom Resolution in a Phase 2 Study in Adult Patients with Staphylococcus aureus bacteremia

Open forum infectious diseases, 2021-12, Vol.8 (Supplement_1), p.S811-S811

2021

Volltextzugriff (PDF)

Duration of asthma and physiologic outcomes in elderly nonsmokers

American journal of respiratory and critical care medicine, 2000-10, Vol.162 (4), p.1423-1428

2000

Volltextzugriff (PDF)

Activity of Lysin CF-296 Alone and in Addition to Daptomycin in a Rat Model of Experimental Methicillin-Resistant Staphylococcus aureus Osteomyelitis

Antimicrobial agents and chemotherapy, 2021-05, Vol.65 (6)

2021

Volltextzugriff (PDF)

Safety and Pharmacokinetics of Exebacase in an Infant With Disseminated Staphylococcus aureus Infection

Clinical infectious diseases, 2022-08, Vol.75 (2), p.338-341

2022

Volltextzugriff (PDF)

Bronchodilator efficacy of the fixed combination of ipratropium and albuterol compared to albuterol alone in moderate-to-severe persistent asthma

Pulmonary pharmacology & therapeutics, 2008-08, Vol.21 (4), p.630-636

2008

Volltextzugriff (PDF)

Efficacy assessment of lysin CF-296 in addition to daptomycin or vancomycin against Staphylococcus aureus in the murine thigh infection model

Journal of antimicrobial chemotherapy, 2021-10, Vol.76 (10), p.2622-2628

2021

Volltextzugriff (PDF)

Exebacase in Addition to Daptomycin Is More Active than Daptomycin or Exebacase Alone in Methicillin-Resistant Staphylococcus aureus Osteomyelitis in Rats

Antimicrobial agents and chemotherapy, 2019-10, Vol.63 (10)

2019

Volltextzugriff (PDF)

Effect of the Lysin Exebacase on Cardiac Vegetation Progression in a Rabbit Model of Methicillin-Resistant Staphylococcus aureus Endocarditis as Determined by Echocardiography

Antimicrobial agents and chemotherapy, 2020-06, Vol.64 (7)

2020

Volltextzugriff (PDF)

711. Exebacase (Lysin CF-301) Activity Against Staphylococcus aureus (S. aureus) Isolates From Bacteremic Patients Enrolled in a Phase 2 Study (CF-301-102)

Open forum infectious diseases, 2019-10, Vol.6 (Supplement_2), p.S320-S320

2019

Volltextzugriff (PDF)

Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial

Annals of internal medicine, 2005-09, Vol.143 (5), p.317

2005

Volltextzugriff (PDF)

Exebacase in Addition to Standard-of-Care Antibiotics for Staphylococcus aureus Bloodstream Infections and Right-Sided Infective Endocarditis: A Phase 3, Superiority-Design, Placebo-Controlled, Randomized Clinical Trial (DISRUPT)

Clinical infectious diseases, 2024-06, Vol.78 (6), p.1473-1481

2024

Volltextzugriff (PDF)

1324. Target Attainment of Exebacase, a First-In-Class Antibacterial Lysin, to Determine Optimal Doses for Adult Patients with Staphylococcus aureus ( S. aureus ) Bloodstream Infections (Bacteremia) Including Endocarditis

Open forum infectious diseases, 2020-12, Vol.7 (Supplement_1), p.S673-S673

2020

Volltextzugriff (PDF)

1 – 25 von 47

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(47)
Mit Volltextzugriff
(44)

Publikationsform

Artikel
(47)

Sprache

Englisch
(47)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(28)
Science & Technology
(28)
Humans
(17)
Microbiology
(14)
Pharmacology & Pharmacy
(13)
Female
(11)
Male
(11)
Middle Aged
(10)
Exebacase
(9)
Lysin
(9)
Staphylococcus Aureus
(9)
Aged
(8)
Abstracts
(7)
Adult
(7)
Respiratory System
(7)
Anti-Bacterial Agents - Pharmacology
(6)
Experimental Therapeutics
(6)
General & Internal Medicine
(6)
Biological And Medical Sciences
(5)
Cf-301
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Direct Lytic Agents: Novel, Rapidly Acting Potential Antimicrobial Treatment Modalities for Systemic Use in the Era of Rising Antibiotic Resistance

In vitro activity of exebacase against methicillin-resistant Staphylococcus aureus biofilms on orthopedic Kirschner wires

Postantibiotic and Sub-MIC Effects of Exebacase (Lysin CF-301) Enhance Antimicrobial Activity against Staphylococcus aureus

Arthroscopic “Debridement and Implant Retention” With Local Administration of Exebacase (Lysin CF-301) Followed by Suppressive Tedizolid as Salvage Therapy in Elderly Patients for Relapsing Multidrug-Resistant S. epidermidis Prosthetic Knee Infection

Exebacase Demonstrates In Vitro Synergy with a Broad Range of Antibiotics against both Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureus

Clinical Trial Design Considerations in Assessing Long-Term Functional Impacts of Tiotropium in COPD: The Uplift Trial

The Antistaphylococcal Lysin, CF-301, Activates Key Host Factors in Human Blood To Potentiate Methicillin-Resistant Staphylococcus aureus Bacteriolysis

Exebacase Is Active In Vitro in Pulmonary Surfactant and Is Efficacious Alone and Synergistic with Daptomycin in a Mouse Model of Lethal Staphylococcus aureus Lung Infection

In vitro activity of Exebacase (CF-301) against clinical Staphylococcus aureus surveillance isolates from the United States, Europe, and Latin America, 2015–2017

Development of a Broth Microdilution Method for Exebacase Susceptibility Testing

Antimicrobial Activity of Exebacase (Lysin CF-301) against the Most Common Causes of Infective Endocarditis

Correction for Oh et al., “Development of a Broth Microdilution Method for Exebacase Susceptibility Testing”

Exebacase for patients with Staphylococcus aureus bloodstream infection and endocarditis

LB12. Exebacase Shows Rapid Symptom Resolution in a Phase 2 Study in Adult Patients with Staphylococcus aureus bacteremia

Duration of asthma and physiologic outcomes in elderly nonsmokers

Activity of Lysin CF-296 Alone and in Addition to Daptomycin in a Rat Model of Experimental Methicillin-Resistant Staphylococcus aureus Osteomyelitis

Safety and Pharmacokinetics of Exebacase in an Infant With Disseminated Staphylococcus aureus Infection

Bronchodilator efficacy of the fixed combination of ipratropium and albuterol compared to albuterol alone in moderate-to-severe persistent asthma

Efficacy assessment of lysin CF-296 in addition to daptomycin or vancomycin against Staphylococcus aureus in the murine thigh infection model

Exebacase in Addition to Daptomycin Is More Active than Daptomycin or Exebacase Alone in Methicillin-Resistant Staphylococcus aureus Osteomyelitis in Rats

Effect of the Lysin Exebacase on Cardiac Vegetation Progression in a Rabbit Model of Methicillin-Resistant Staphylococcus aureus Endocarditis as Determined by Echocardiography

711. Exebacase (Lysin CF-301) Activity Against Staphylococcus aureus (S. aureus) Isolates From Bacteremic Patients Enrolled in a Phase 2 Study (CF-301-102)

Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial

Exebacase in Addition to Standard-of-Care Antibiotics for Staphylococcus aureus Bloodstream Infections and Right-Sided Infective Endocarditis: A Phase 3, Superiority-Design, Placebo-Controlled, Randomized Clinical Trial (DISRUPT)

1324. Target Attainment of Exebacase, a First-In-Class Antibacterial Lysin, to Determine Optimal Doses for Adult Patients with Staphylococcus aureus ( S. aureus ) Bloodstream Infections (Bacteremia) Including Endocarditis

Suchergebnisse filtern